Pfizer Ventures

Pfizer Ventures is the strategic corporate venture capital arm of Pfizer Inc., established in 2004 and headquartered in New York. It invests globally in private biopharmaceutical and life sciences companies across the full private company lifecycle, from Seed through pre-IPO, with a strong emphasis on early-stage investments. Core therapeutic focus areas include Oncology, Inflammation & Immunology, Cardiovascular, Metabolic/Obesity, and Vaccines; the fund also backs platform technology companies with diversified pipelines aligned to these areas. Typical initial check size is $5–$20 million, with reserved allocation for follow-on financings. Pfizer Ventures can lead or join investor syndicates and seeks board representation commensurate with its investment level. It does not require product or technology rights as a condition of investment. Total capital commitment is reported at approximately $900 million, including a top-up announced in Q4 2021. Portfolio companies gain access to Pfizer's scientific network, clinical insight, and potential strategic collaboration. Opportunities can be submitted via the Pfizer partnering portal.